Advances in molecular targeted treatment for head and neck cancer / 国际肿瘤学杂志

ABSTRACT

Toxicity has impeded the advance of chemoradiotherapy for head and neck cancer, while targeted therapy has demonstrated some advantage. Over the past decade, targeted therapy is becoming the important section in multimodal approaches for head and neck cancer. Targeted drugs include monoclonal antibodies, small molecular chemicals and antisense oligodeoxynucleotide, etc. Cetuximab is the only targeted agent approved for this malignancy, and other targeted drugs, such as gefitinib and lapatinib, have demonstrated encouraging outcome in phase Ⅰ -Ⅲ clinical trials for head and neck cancer.